T-Dxd
HER2 Overexpression
Tianjin Medical University Cancer Institute and Hospitalantibody_drug_conjugateActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the HER2 Overexpression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
cgt4255 Cogent Biosciences, Inc. | Phase 1 | CC |
Same molecule, other indications
T-Dxd is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →